Anaphylactoid reactions might occur (avoid use in bronchospasm, asthma, rhinitis, or urticaria with NSAID therapy). May prolong bleeding time. Anemia might occur. Increased risk of cardiovascular thrombotic events (MI, stroke, and new onset or worsening of pre-existing hypertension)(use caution with fluid retention, heart failure, or hypertension). May increase risk of GI irritation, inflammation, ulceration, bleeding, and perforation (use caution with history of GI disease (bleeding or ulcers), concurrent therapy with aspirin, anticoagulants and/or corticosteroids, smoking, use of alcohol, elderly or debilitated patients). Hypersensitivity syndrome reported. Diflunisal is possibly associated with Reye’s syndrome. May cause exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis. Caution in decreased hepatic function (severe hepatic reactions occurred). May compromise existing renal function (patients with impaired renal function, dehydration, heart failure, liver dysfunction, those taking diuretics, and ACE inhibitors, and the elderly are at greater risk of renal toxicity). Withhold for at least 4-6 half-lives prior to surgical or dental procedures. NSAID formulations reversibly decrease platelet aggregation via mechanisms different than those observed with aspirin, therefore caution should be exercised in the use of NSAIDs in patients already on anticoagulant therapy with drugs such as warfarin.